<DOC>
	<DOCNO>NCT00579982</DOCNO>
	<brief_summary>To determine convenience satisfaction new orally disintegrate tablet formulation ( ODT ) lamictal subject mood disorder . This multicenter , open-label study participant mood disorder , report difficulty discomfort swallow currently market IR compress tablet formulation lamotrigine person ( spouse , partner , companion , aid , nurse , caregiver , etc ) willing complete Companion/Caregiver Question . Subjects switch currently market lamotrigine IR formulation match dose lamotrigine IR orally disintegrate tablet ( ODT ) 3 week determine convenience satisfaction .</brief_summary>
	<brief_title>An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Subject must document diagnosis mood disorder define Diagnostic Statistical Manual Mental Disorders ( DSM ) IV ( 296.00296.90 ) . Subject must person ( spouse , partner , companion , aid , nurse , caregiver , etc ) willing complete Companion/Caregiver Preference Question either person via telephone . This individual must read , write , comprehend English level sufficient complete studyrelated assessment . Subject must take stable dose currently market compressed tablet formulation lamotrigine IR least 4 week prior Baseline ( Day 1 ) study must adherent prescribed dose regimen . The current dose must exceed 600 mg/day . Subject 's current lamotrigine IR dose , frequency number tablet per administration must remain consistent IR ODT regimens . However , subject 's current lamotrigine IR dose may subject would receive one additional ODT per administration order equal IR dose . Subject must currently report difficulty discomfort swallow lamotrigine IR compress tablet , nature document . NOTE : A diagnosis dysphagia require . Subject must ability comprehend consent form provide inform consent . Subject must read , write , comprehend English level sufficient complete studyrelated assessment . Subject male female least 18 year age . If female , subject eligible enter participate study lactating : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female premenarchal postmenopausal [ define one year without menses ] ) ; surgically sterile [ via hysterectomy and/or removal ovary ] , 2. childbearing potential , negative pregnancy test Screening and/or Baseline ( prior Investigational Product administration ) , agree one following requirement : male sexual partner surgically sterilize ( vasectomy documentation azoospermia ) prior Screening , sexual partner ( ) is/are exclusively female , double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) . The subject must use method least 1 week follow discontinuation Investigational Product , intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year . Acceptable IUDs , purpose study , include TCu380A ( Paragard ) , TCU380 Slimline ( Gyne T Slimline ) , MULTILOAD250 ( MLCu250 ) 375 , Levonorgesterol LNG20 Intrauterine System ( Mirena/Levonova ) , Flexigard 330/CuFix PP330 ( Gynefix ) .The subject must device insert least 2 week prior Screening , throughout study , 2 week follow discontinuation Investigational Product . Subject : current ( within six month prior Screening ) diagnosis anorexia nervosa bulimia . diagnosis mood disorder due general medical condition , substance abuse per DSMIV ( 293.83 ) . diagnosis schizophrenia psychotic disorder . Subject meet current criterion acute mood disorder CGIS â‰¥4 Screening . Subject crush lamotrigine IR compress tablet prior take receive medication orally . Subject , investigator 's judgment , pose homicidal serious suicidal risk ; make suicide attempt within six month precede Screening ; ever homicidal . Subject score 1 great Suicidality item ( Item 9 ) BDIII Screening and/or Baseline . Subject ever experience rash relate prior lamotrigine treatment , treatment discontinue clinically significant safety reason . Subject history severe hepatobiliary disease within past 3 year . Subject medical condition , investigator 's judgment , consider clinically significant could potentially affect subject safety study outcome . Subject positive urine test Screening illicit drug use and/or history alcohol substance abuse dependence within past 12 month . Subject currently participate another clinical study subject expose investigational noninvestigational drug device , do within precede month study unrelated current illness , six month study relate current illness . Female subject pregnant , lactating , agree use contraceptive method ( ) specify protocol avoid pregnancy study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mood disorder</keyword>
</DOC>